Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Abstract

loading...

About

This paper, published in 1950, received 316 indexed citations. Written by Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima, George Scott, Dylan Birchard, Seblewongel Asrat, Yu Bai, Wei Keat Lim, Joel Martin and Tammy Huang covering the research area of Immunology, Physiology and Dermatology. It is primarily cited by scholars working on Physiology (188 citations), Immunology and Allergy (142 citations) and Dermatology (97 citations). Published in Allergy.

Countries where authors are citing Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Since Specialization
Citations

This map shows the geographic impact of Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation more than expected).

Fields of papers citing Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1111/all.14151.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026